Tumour Risk
Cross-source consensus on Tumour Risk from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Highlighted claims
- P/LP variant carriers had substantially higher overall and malignant tumour incidence than children without P/LP or VUS-LP variants. — Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing
- P/LP carriers had poorer tumour-free probability and higher cumulative incidence than other patients. — Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing
- Cumulative tumour incidence increased notably after age 5 among P/LP and VUS-LP carriers. — Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing
- VUS-LP carriers had higher overall tumour incidence than children without P/LP or VUS-LP variants. — Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing
- For malignant tumours, VUS-LP carriers did not show a higher incidence rate than the no-variant group in this study. — Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing